CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018 . The management team will host a conference call on Wednesday, May 2,

--Data to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 11, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced the presentation of new findings at the American Association for Cancer Research (AACR)

-- FoundationOne CDx is the First Next Generation Sequencing Test for All Solid Tumors to Complete the FDA /CMS Parallel Review Process and Launch with National Medicare Coverage -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that FoundationOne CDx™,

-- Final NCD Significantly Expands Patient Access Beyond the Preliminary NCD -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Centers for Medicare & Medicaid Services (CMS) issued a final National Coverage Determination (NCD) for patients who

-- Chugai to Commercialize Foundation Medicine's Suite of Comprehensive Genomic Profiling (CGP) Services in Japan , Expanding Patient Access to Personalized Cancer Care -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co.

CAMBRIDGE, Mass. & REDWOOD CITY, Calif. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc . announced an agreement to settle false advertising challenges that the companies had filed against each other under the Lanham Act related to advertising for their

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company's 38 th Annual Healthcare Conference on Wednesday, March 14, 2018 , at 10:40 a.m. ET in Boston .

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2017. Highlights for the quarter and year included: Fourth quarter revenue of $48.9 million, 70% year-over-year growth; Full year

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018 . The management team will host a conference call on Wednesday, March 7,

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) and the European Organisation for Research and Treatment of Cancer (EORTC) announced today a collaboration in which Foundation Medicine's comprehensive genomic profiling (CGP) tests will be used to inform patient